Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

NCT02331368 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

PROCEDURE: Autologous Stem Cell Transplant
DRUG: Melphalan
DRUG: Lenalidomide
DRUG: MK-3475

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]